Zobrazeno 1 - 10
of 188
pro vyhledávání: '"Philippe, Aftimos"'
Autor:
Magdalena Mileva, Elisabeth G. E. de Vries, Thomas Guiot, Zéna Wimana, Anne-Leen Deleu, Carolien P. Schröder, Yolene Lefebvre, Marianne Paesmans, Sigrid Stroobants, Manon Huizing, Philippe Aftimos, Jolien Tol, Winette T. A. Van der Graaf, Wim J. G. Oyen, Danielle J. Vugts, C. Willemien Menke-van der Houven van Oordt, Adrienne H. Brouwers, Martine Piccart-Gebhart, Patrick Flamen, Géraldine Gebhart
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Efficacy of the human epidermal growth factor receptor (HER)2-targeting trastuzumab emtansine (T-DM1) in breast cancer (BC) relies on HER2 status determined by immunohistochemistry or fluorescence in-situ hybridization. Heterogeneity in HER2
Externí odkaz:
https://doaj.org/article/b8159ecb1674471b9a212c77843626e6
Autor:
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase II, open-label trial evaluating
Externí odkaz:
https://doaj.org/article/50f0c9a693404d0bbb0bf5ae3d4ee9c1
Autor:
Guilherme Nader-Marta, Chiara Molinelli, Véronique Debien, Diogo Martins-Branco, Philippe Aftimos, Evandro de Azambuja, Ahmad Awada
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Antibody–drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB) targeting a specific target antigen, a cytotoxic payload, and a linker binding the antibody to th
Externí odkaz:
https://doaj.org/article/7a5ff39dd5c6423c93c2492ba0e8da2b
Autor:
Elisa Agostinetto, Lieveke Ameye, Samuel Martel, Philippe Aftimos, Noam Pondé, Christian Maurer, Sarra El-Abed, Yingbo Wang, Malou Vicente, Saranya Chumsri, Judith Bliss, Judith Kroep, Marco Colleoni, Fausto Petrelli, Lucia Del Mastro, Alvaro Moreno-Aspitia, Martine Piccart, Marianne Paesmans, Evandro de Azambuja, Matteo Lambertini
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated its prognostic perfo
Externí odkaz:
https://doaj.org/article/26e9c2c289cb4f0e805a3be45e4ff06d
Autor:
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/1872bd3c329443328fa10ee0e5e38651
Autor:
Fabio Conforti, Laura Pala, Eleonora Pagan, Elena Guerini Rocco, Vincenzo Bagnardi, Emilia Montagna, Giulia Peruzzotti, Tommaso De Pas, Caterina Fumagalli, Silvana Pileggi, Chiara Pesenti, Sergio Marchini, Giovanni Corso, Caterina Marchio’, Anna Sapino, Rossella Graffeo, Laetitia Collet, Philippe Aftimos, Christos Sotiriou, Martine Piccart, Richard D. Gelber, Giuseppe Viale, Marco Colleoni, Aron Goldhirsch
Publikováno v:
Breast, Vol 59, Iss , Pp 94-101 (2021)
Background: We report here for the first time, a comprehensive characterization of biological and clinical features of early-stage triple negative Invasive Lobular Carcinomas(TN-ILCs) Methods: We analyzed all consecutive patients with early-stage TN-
Externí odkaz:
https://doaj.org/article/0e41cdfb84f743128a8f6f2c40685bb2
Autor:
Ali Bohlok, Peter Vermeulen, Sophia Leduc, Emily Latacz, Lara Botzenhart, François Richard, Maxim De Schepper, Tatjana Geukens, Valerio Lucidi, Michail Ignatiadis, Philippe Aftimos, Christos Sotiriou, Martine Piccart, Alain Hendlisz, Steven Van Laere, Luc Dirix, Jean-Christophe Noël, Elia Biganzoli, Denis Larsimont, Christine Desmedt, Vincent Donckier
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-5 (2020)
Abstract Currently, there are no markers to identify patients with liver-only or liver-dominant metastases that would benefit from hepatic surgery. Here we characterized histopathological growth patterns (HGPs) of liver metastases in a consecutive se
Externí odkaz:
https://doaj.org/article/5c79b68166d04ad68699b274c384a172
Autor:
Kamal S. Saini, Begoña de las Heras, Ruth Plummer, Victor Moreno, Marco Romano, Javier de Castro, Philippe Aftimos, Judy Fredriksson, Gouri Shankar Bhattacharyya, Martin Sebastian Olivo, Gaia Schiavon, Kevin Punie, Jesus Garcia-Foncillas, Ernesto Rogata, Richie Pfeiffer, Cecilia Orbegoso, Kenneth Morrison, Giuseppe Curigliano, Lynda Chin, Monika Lamba Saini, Øystein Rekdal, Steven Anderson, Javier Cortes, Manuela Leone, Janet Dancey, Chris Twelves, Ahmad Awada
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 1357-1362 (2020)
Externí odkaz:
https://doaj.org/article/e753a4f9fda043498869674261249653
Autor:
Agnes Jager, Elisabeth G. E. de Vries, C. Willemien Menke-van der Houven van Oordt, Patrick Neven, Clasina M. Venema, Andor W. J. M. Glaudemans, Yamei Wang, Rebecca G. Bagley, Maureen G. Conlan, Philippe Aftimos
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in lesions from postmeno
Externí odkaz:
https://doaj.org/article/b93108018a2e49f1b6e045dbee2472a8
Autor:
Diogo Martins-Branco, Chiara Molinelli, Guilherme Nader Marta, Lieveke Ameye, Marianne Paesmans, Roberto Salgado, Philippe Aftimos, Evandro de Azambuja
Publikováno v:
Cancer Research. 83:P1-07
Background: Neoadjuvant treatment allows to better distinguish responders from non-responders, and to tailor post-neoadjuvant treatment according to tumor response in patients with HER2+ and triple-negative early breast cancer. For HR+/HER2- tumors,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a1a157545c167fffadac0f3e9288d03
https://doi.org/10.1158/1538-7445.sabcs22-p1-07-01
https://doi.org/10.1158/1538-7445.sabcs22-p1-07-01